The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
Recruiting
- Conditions
- IgA Nephropathy
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT04858724
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, Shanghai, China
Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study
Phase 4
- Conditions
- Follicular Lymphoma
- Interventions
- Drug: BR for 6 cycles +R for 8 cyclesDrug: R2 for 6 cycles + R2 maintenanceDrug: RCHOP for 6 cycles +R for 8 cycles
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 789
- Registration Number
- NCT04842318
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, China
Study of Roxadustat in the Treatment of Acute Myocardial Infarction
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 158
- Registration Number
- NCT04803864
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT
Phase 3
- Conditions
- Lymphoma, Large B-Cell, DiffuseTransplantationChemotherapy
- Interventions
- Drug: PD-1 Inhibitor Tislelizumab maintenance therapy
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT04799314
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Safety and Immunogenicity of an Inactivated Vaccine Against COVID-19 in Medical Workers
- Conditions
- Covid19SARS-CoV-2 Infection
- Interventions
- Biological: SARS-CoV-2 Vaccine(Vero Cell), Inactivated
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 1370
- Registration Number
- NCT04795414
- Locations
- 🇨🇳
Ruijin Hospital affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, Shanghai, China
PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT
Phase 3
- Conditions
- Lymphoma, Large B-Cell, DiffuseTransplantationChemotherapy
- Interventions
- Drug: PD-1 Inhibitor Tislelizumab maintenance therapy
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 94
- Registration Number
- NCT04789434
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer
Phase 1
- Conditions
- Stage IIIC Gastric Cancer
- Interventions
- Drug: Nab-PTX, Sintilimab, S-1
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT04781413
- Locations
- 🇨🇳
Department of Surgery, Ruijin Hospital, Shanghai, China
Combination Therapy for First Line Treatment of Advanced Cervical Cancer
Phase 1
- Conditions
- Advanced Cervical Cancer
- Interventions
- Drug: Anlotinib, Toripalimab, Paclitaxel, Cisplatin/ Carboplatin
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04731038
- Locations
- 🇨🇳
Department of Oncology, Ruijin Hospital, Shanghai, China
Cardiac Fibroblast Activation Detected by 68Ga-FAPI PET/MR
Not Applicable
Completed
- Conditions
- Myocardial Remodeling After AMI
- Interventions
- Diagnostic Test: 68Ga-FAPI PET/MRI
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 89
- Registration Number
- NCT04723953
- Locations
- 🇨🇳
Shanghai Ruijin Hospital, Shanghai, China
Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL
Phase 2
- Conditions
- Primary Mediastinal Large B Cell LymphomaEBV-Positive DLBCL, Nos
- Interventions
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04705129
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath